BUZZ-抑郁症药物进入后期试验阶段，AtaiBeckley 股价上升

路透中文

Mar 10

BUZZ-抑郁症药物进入后期试验阶段，AtaiBeckley 股价上升

3月10日 - ** 制药商 AtaiBeckley ATAI.O 股价盘前上涨 1.29% 至 3.94 美元

** 该公司称，在获得FDA的积极反馈后，其抑郁症实验药物BPL-003将于2026年第二季度进入后期测试阶段

** 称BPL-003主要针对耐药性抑郁症，这是一种普通疗法无效的严重抑郁症

** 补充说，鼻腔喷雾药物在中期研究中显示出快速、持久的疗效，两天后就能看到效果，并能持续八周之久

** 即将进行的两项为期 12 周的试验以及一项为期一年的延长试验将测试该药物与安慰剂的效果 - ATAI

** 公司重申现金流将持续到 2029 年初，并报告了焦虑症药物 EMP-01 和抑郁症药物 VLS-01 的进展情况

** 2025 年，ATAI 增长了约三倍

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2618399759"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618399759\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618399759?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-10 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618399759","market":"us","top_or_hot":-1,"title":"BUZZ-抑郁症药物进入后期试验阶段，AtaiBeckley 股价上升","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-抑郁症药物进入后期试验阶段，AtaiBeckley 股价上升</title></head><body><p><span>3月10日</span><span> - </span>** 制药商 AtaiBeckley <span>ATAI.O</span> 股价盘前上涨 1.29% 至 3.94 美元 </p><p>** 该公司称，在获得FDA的积极反馈后，其抑郁症实验药物BPL-003将于2026年第二季度进入后期测试阶段</p><p>** 称BPL-003主要针对耐药性抑郁症，这是一种普通疗法无效的严重抑郁症</p><p>** 补充说，鼻腔喷雾药物在中期研究中显示出快速、持久的疗效，两天后就能看到效果，并能持续八周之久</p><p>** 即将进行的两项为期 12 周的试验以及一项为期一年的延长试验将测试该药物与安慰剂的效果 - ATAI</p><p>** 公司重申现金流将持续到 2029 年初，并报告了焦虑症药物 EMP-01 和抑郁症药物 VLS-01 的进展情况</p><p>** 2025 年，ATAI 增长了约三倍</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-抑郁症药物进入后期试验阶段，AtaiBeckley 股价上升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-抑郁症药物进入后期试验阶段，AtaiBeckley 股价上升\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-03-10 18:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-抑郁症药物进入后期试验阶段，AtaiBeckley 股价上升</title></head><body><p><span>3月10日</span><span> - </span>** 制药商 AtaiBeckley <span>ATAI.O</span> 股价盘前上涨 1.29% 至 3.94 美元 </p><p>** 该公司称，在获得FDA的积极反馈后，其抑郁症实验药物BPL-003将于2026年第二季度进入后期测试阶段</p><p>** 称BPL-003主要针对耐药性抑郁症，这是一种普通疗法无效的严重抑郁症</p><p>** 补充说，鼻腔喷雾药物在中期研究中显示出快速、持久的疗效，两天后就能看到效果，并能持续八周之久</p><p>** 即将进行的两项为期 12 周的试验以及一项为期一年的延长试验将测试该药物与安慰剂的效果 - ATAI</p><p>** 公司重申现金流将持续到 2029 年初，并报告了焦虑症药物 EMP-01 和抑郁症药物 VLS-01 的进展情况</p><p>** 2025 年，ATAI 增长了约三倍</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL4S3ZY0V9:1","article_id":"2618399759","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618399759","pubTimestamp":1773138098,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","BK4007":"制药","INKT":"MiNK Therapeutics, Inc.","ATAI":"Atai Beckley Inc"},"translate_title":"BUZZ-AtaiBeckley stock rises as depression drug enters late-stage trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INKT":0.9,"ATAI":0.9},"content_text":"BUZZ-抑郁症药物进入后期试验阶段，AtaiBeckley 股价上升3月10日 - ** 制药商 AtaiBeckley ATAI.O 股价盘前上涨 1.29% 至 3.94 美元 ** 该公司称，在获得FDA的积极反馈后，其抑郁症实验药物BPL-003将于2026年第二季度进入后期测试阶段** 称BPL-003主要针对耐药性抑郁症，这是一种普通疗法无效的严重抑郁症** 补充说，鼻腔喷雾药物在中期研究中显示出快速、持久的疗效，两天后就能看到效果，并能持续八周之久** 即将进行的两项为期 12 周的试验以及一项为期一年的延长试验将测试该药物与安慰剂的效果 - ATAI** 公司重申现金流将持续到 2029 年初，并报告了焦虑症药物 EMP-01 和抑郁症药物 VLS-01 的进展情况** 2025 年，ATAI 增长了约三倍(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}